Anticancer polypyrrole-polyethylenimine drug-free nanozyme for precise B-cell lymphoma therapy

Thi Thuy Nguyen, Er Yuan Chuang, Ya Ping Chen, Po Chun Tseng, Ming Kai Jhan, Chun Yi Lai, Yung Ting Wang, Yu Ping Hung, Chun Austin Changou, Chi Ming Lee, Chia Ling Chen, Chiou Feng Lin

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


As an alternative strategy for cancer treatment, the combination of cancer nanomedicine and immunotherapy is promising with regard to efficacy and safety; however, precise modulation of the activation of antitumor immunity remains challenging. Therefore, the aim of the present study was to describe an intelligent nanocomposite polymer immunomodulator, drug-free polypyrrole-polyethyleneimine nanozyme (PPY-PEI NZ), which responds to the B-cell lymphoma tumor microenvironment, for precision cancer immunotherapy. Earlier engulfment of PPY-PEI NZs in an endocytosis-dependent manner resulted in rapid binding in four different types of B-cell lymphoma cells. The PPY-PEI NZ effectively suppressed B cell colony-like growth in vitro accompanied by cytotoxicity via apoptosis induction. During PPY-PEI NZ-induced cell death, mitochondrial swelling, loss of mitochondrial transmembrane potential (MTP), downregulation of antiapoptotic proteins, and caspase-dependent apoptosis were observed. Deregulated AKT and ERK signaling contributed to glycogen synthase kinase-3-regulated cell apoptosis following deregulation of Mcl-1 and MTP loss. Additionally, PPY-PEI NZs induced lysosomal membrane permeabilization while inhibiting endosomal acidification, partly protecting cells from lysosomal apoptosis. PPY-PEI NZs selectively bound and eliminated exogenous malignant B cells in a mixed culture system with healthy leukocytes ex vivo. While PPY-PEI NZs showed no cytotoxicity in wild-type mice, they provided long-term and efficient inhibition of the growth of B-cell lymphoma-driven nodules in a subcutaneous xenograft model. This study explores a potential PPY-PEI NZ-based anticancer agent against B-cell lymphoma.

Original languageEnglish
Article number114397
JournalBiomedicine and Pharmacotherapy
Publication statusPublished - 2023 Apr

All Science Journal Classification (ASJC) codes

  • Pharmacology


Dive into the research topics of 'Anticancer polypyrrole-polyethylenimine drug-free nanozyme for precise B-cell lymphoma therapy'. Together they form a unique fingerprint.

Cite this